Table 2.
Clinical characteristics of participants by study group
| Parameters | PCOS group n = 6 | Control group n = 6 | Difference between groupsa | ||
|---|---|---|---|---|---|
| Mean (± SD) | Mean (± SD) | Adjusted mean difference (95%CI)b | p value | q value | |
| Age | 30.250 (4.3725) | 27.429 (2.507) | 0.71 (− 0.26 to 1.67) | 0.139 | 0.175 |
| Years of infertility | 3.750 (1.960) | 2.429 (0.976) | 0.75 (− 0.22 to 1.72) | 0.116 | 0.168 |
| Body mass index (BMI)c | 23.390 (2.131) | 22.366 (2.202) | 0.45 (− 0.49 to 1.40) | 0.332 | 0.319 |
| Luteinizing hormone (LH) IU/Ld | 13.077 (3.741) | 5.029 (1.924) | 2.39 (1.12 to 3.65) | < 0.001 | < 0.001 |
| Follicle stimulating hormone (FSH) IU/Ld | 5.178 (1.303) | 6.410 (1.903) | − 0.76 (− 1.73 to 0.21) | 0.111 | 0.168 |
| LH:FSH ratio | 2.514 (0.399) | 0.804 (0.278) | 4.52 (2.66 to 6.39) | < 0.001 | |
| Estradiol (E2) pmol/Ld | 147.4 (38.756) | 140.057 (146.376) | 0.08 (− 0.86 to 1.01) | 0.870 | 0.678 |
| Testosterone nmol/L | 2.023 (0.287) | 0.697 (0.334) | 4.16 (2.41 to 5.92) | < 0.001 | < 0.001 |
| Prolactin (PRL)mIU/Ld | 349.016 (214.871) | 363.9 (132.897) | − 0.08 (− 1.02 to 0.87) | 0.873 | 0.678 |
| Anti-mullerian hormone (AMH)ng/ml | 9.933 (5.628) | 4.450 (1.800) | 1.13 (0.11 to 2.14) | 0.024 | 0.048 |
| Progesterone (P)nmol/L | 0.452 (0.275) | 0.657 (0.653) | − 0.44 (− 1.38 to 0.51) | 0.347 | 0.319 |
| Fasting glucose nmol/L | 5.023 (0.412) | 5.216 (0.296) | − 0.49 (− 1.44 to 0.46) | 0.294 | 0.319 |
| Sinus follicle number | 32.167 (10.098) | 20.857 (4.981) | 1.25 (0.22 to 2.28) | 0.014 | 0.034 |
aAll results are reported after adjustment for baseline values using ANCOVA
bIntervention effects are quantified as differences between groups in the mean value for each scale, estimated using linear regression models that adjusted for recruitment site and language of interview
cBMI = bodyweight (kg) divided by height (metres) squared. (BMI = w(kg)/height(m)2)
dLog transformations were carried out on the data before analyses